July 28, 2026 11:17 AM EDT
News Briefing
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source
Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3
Incyte drops JAK2 drug INCB160058 after data review; Oak Hill Bio merges with RA Capital SPAC for $175M; Innocare's fadeucravacitinib hits Phase 3 endpoint in psoriasis.
115 words~1 min read
